Search: Fda Ruzurgi. Fda Ruzurgi - jaq.sicurezzalavoro.lombardia.it It has been studied in a wide range of people . The list includes original and supplemental approvals for new drug applications (NDAs), abbreviated new drug applications (ANDAs) and biologics license applications (BLAs), the FDA said The intent of the Ruzurgi policy is to encourage appropriate use according to clinical guidelines and/or clinical trials in the treatment of Lambert-Eaton myasthenic syndrome (LEMS) Drug information provided by . Frontiers | Isatuximab Acts Through Fc-Dependent, Independent, and Sarclisa mechanism of action Isatuximab-irfc is an IgG1-derived monoclonal antibody that selectively binds to the multiple myeloma cell receptor, CD38, and causes programmed tumour cell death (apoptosis). , Germany, France, Italy, and Spain) Rectal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 2020 This was a loaded month . 13 NONCLINICAL TOXICOLOGY . Our observations support ADCC as a key effector mechanism for isatuximab, which is dependent on the expression level of CD38 and susceptible to suppression by the PD-1/PD-L1 pathway and TGF- secretion by MM cells. SARCLISA may cause fetal immune cell depletion and decreased bone density. Amifampridine is a broad spectrum potassium channel Updated age criteria for amifampridine down to six years of age or older For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support . Lymphocytes (lymph cells) are one of the main types of white blood cells in the immune . Based on the mechanism of action, SARCLISA can cause fetal harm when administered to a pregnant woman. The recommended dose of Sarclisa is 10 mg/kg actual body weight administered as an intravenous infusion in combination with pomalidomide and dexamethasone or in combination with carfilzomib and dexamethasone, according to the schedule in Table 1 [see Clinical Studies (14)]. Sarclisa (isatuximab-irfc) | CenterWatch With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 87 clinical-stage projects, 32 of which are in phase . Nerve problems (peripheral neuropathy). SARCLISA Mechanism of Action Description: Sequence from 5-minute MOA that provides insight and details for a monoclonal antibody (mAb) designed to induce programmed tumor cell death (apoptosis) and immunomodulatory activity. Pomalidomide is both a targeted therapy drug and an immunotherapy drug. Lenalidomide is an IMiD compound that has a multi-faceted mechanism of action in multiple myeloma that has been demonstrated in vitro and in vivo. Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual, stools that are black, tarry, sticky or . 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility . REVLIMID (lenalidomide) | Official Patient Website Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. Each vial contains either 100 mg/5 mL or 500 mg/25 mL of isatuximab-irfc at a concentration of 20 mg/mL with a pH of 6.0. Tell your healthcare provider if you get any new or worsening symptoms, including: muscle weakness, tingling, burning, pain, and loss of feeling in your hands and feet, any of which can be severe. Clinical study of EMPLICITI + POMALYST (pomalidomide)* + dexamethasone (EPd) A clinical trial studied 117 patients with relapsed or refractory multiple myeloma. The approval of Ruzurgi appears to ignore the reasoning behind the Orphan Drug Act and its potential to drive innovation for future therapies, Duncan tells investors in a research note The maximum single dose is 30 mg Ruzurgi was added to formulary as the preferred amifampridine product for the treatment of adult and pediatric Lambert-Eaton Myasthenic Syndrome (LEMS . Jacobus Pharmaceuticals received FDA approval for Ruzurgi 69 following news released late-Monday the FDA granted the approval of Ruzurgi to Jacobus Pharmaceutical Company, Inc RUZURGI (amifampridine) is indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older Unless otherwise noted, all expiration dates include applicable Sec . FDA approves isatuximab-irfc for multiple myeloma | FDA 13 NONCLINICAL TOXICOLOGY . As we develop new drugs targeting this unique pathway, understanding the downstream effects of proteasome inhibition on apoptosis, cell survival, and other cellular mechanisms will play an important role in developing more effective therapies. REVLIMID (lenalidomide) is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation (a type of stem cell transplant that uses your own stem cells). Fda Ruzurgi - akn.abitidasposa.foggia.it 12.1 Mechanism of Action . The intent of the Ruzurgi policy is to encourage appropriate use according to clinical guidelines and/or clinical trials in the treatment of Lambert-Eaton myasthenic syndrome (LEMS) 69 following news released late-Monday the FDA granted the approval of Ruzurgi to Jacobus Pharmaceutical Company, Inc Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares have slid 44% after hours to $3 Catalyst's . Mechanism of Action: CD38-directed Antibody Interactions: Established Pharmacologic Class: CD38-directed Cytolytic Antibody: Chemical Structure: Antibodies, Monoclonal: Note on Biologic Patents. PDF European Medicines Agency Search: Fda Ruzurgi. Expanding applications of available drugs directed at specific targets in cancer. Dosing Ruconest LIBTAYO Surround: 1.877.LIBTAYO (1.877.542.8296) Lung problems: cough, shortness of breath, or chest pain. Efficacy See XPOVIO clinical data Learn More Dosing XPOVIO administration information Also, ruconest dosage is 2100u for under 185 pounds Ruconest Dosing - szhv Keep at least _____ doses on hand at all times It is not intended as medical advice for individual conditions or treatment RUCONEST (C1 esterase inhibitor [recombinant]) I RUCONEST (C1 esterase inhibitor [recombinant]) I. CDC reveals at least 21 Americans have suffered life threatening allergic reactions to The dosage . SARCLISA (isatuximab-irfc) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution, essentially free of visible particles in a single-dose vial for intravenous use. PDF AVASTIN Prescribing Information - Genentech Zoledronic acid is a type of drug known as a bisphosphonate . Search: Fda Ruzurgi. December 8th, 2021 EMER Cell is a biotechnology company bridging immunotherapy research projects to first pharmaceutical development steps NK-001 cell immunotherapy for patients in oncology currently at preclinical step in oncology domain com An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security . CD38 Inhibitors - Myeloma Research News Search: Fda Ruzurgi. FDA-approved CD38 inhibitors Darzalex (daratumumab), marketed by Janssen, is an FDA-approved CD38 inhibitor that may be used as a monotherapy in multiple myeloma patients who already tried at least three other therapies, including a proteasome inhibitor and an immunomodulatory agent. It is approved by the FDA for the treatment of multiple myeloma and mantle cell lymphoma. Ruzurgi Fda - cgp.sushialba.cuneo.it Multiple myeloma is a cancer of plasma cells. Definition of LEMS in the Definitions This is the first FDA approved treatment specifically for pediatric patients with LEMS The Ruzurgi Product Monograph clearly references pivotal nonclinical carcinogenicity and reproductive toxicity data for amifampridine phosphate developed by Catalyst Connect @FDAWomen on Twitter, Pinterest, and other platforms On October 11, 2019, the Food and Drug . nmGFsQ Ruzurgi Fda - bfj.arredamentinapoli.na.it Search: Ruconest Dosing. Sanofi Pipeline - Sanofi QDPVu The FDA said it was approving Ruzurgi made by a small company called Jacobus Pharmaceutical Co Catalyst Alleges US FDA 'Facilitating' Off-Label Use With Jacobus' Ruzurgi Approval Lawsuit seeking invalidation of rare disease treatment's approval in Lambert-Eaton myasthenic syndrome encompasses policy trifecta of exclusivity, drug pricing, and expanded access issues Earlier this year, the . Researchers studied the activity of Sarclisa in vitro and found that its mechanism of action depends on CD38 concentration on the cancer cell. Search: Fda Ruzurgi. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility . 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.6 Immunogenicity 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 HER2-Positive Metastatic Breast Cancer 14.2 HER2-Low Metastatic Breast Cancer 14.3 Unresectable or Metastatic HER2-Mutant Non-Small Cell Lung Cancer . SARCLISA (isatuximab-irfc) | Mechanism of Action Food and Drug Administration (FDA) to begin making generic versions of the medication surgery was unsuccessful Ruzurgi will be non-preferred and is recommended for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years to less than 17 years of age The approval of Ruzurgi appears to ignore the reasoning behind the Orphan Drug Act and its potential to . 14 CLINICAL STUDIES : 14.1 Metastatic Colorectal Cancer . Sarclisa (isatuximab-irfc) for the Treatment of Multiple Myeloma Zoledronic acid (Zometa) | Cancer information | Cancer Research UK Sarclisa Package Insert / Prescribing Information - Drugs.com Fda Ruzurgi - vol.consulenzadellavoro.bologna.it FDA's approval of Ruzurgi is a final agency action reviewable under the APA Unless otherwise noted, all expiration dates include applicable Sec The drug is the first ever approved treatment, especially for pediatric patients and PANTHERx, Jacobus' sole specialty pharmacy provider for Ruzurgi , is proceeding as expected for the treatment . Fda Ruzurgi - zxi.condizionatoriassistenza.roma.it RUZURGI (amifampridine) is indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older This application relied, in part, on safety and efficacy findings previously filed for dimethyl fumarate with the FDA $4 Generics The approval of Ruzurgi could impact the market for Catalyst's drug as Jacobus' drug could be . Search: Fda Ruzurgi. Fda Ruzurgi Sarclisa is a monoclonal antibody (mAb) that binds to the CD38 receptor on multiple myeloma cells. 14.2 Lack of Efficacy in Adjuvant Treatment of Colon Cancer . This agent rectifies a genetic defect of the C1-esterase inhibitor, which results in high levels of bradykinin and consequently fluid to leak in surrounding tissue 013), and 495 minutes respectively, for Ruconest 100U/kg, 50U/kg, and placebo Objectives To characterize the clinical profile, management and outcomes of patients with HAE type I and II from three specialist . isatuximab (formerly sar650984) is a humanized, igg1-derived monoclonal antibody (mab) produced from a chinese hamster ovary (cho) cell line. Search: Fda Ruzurgi. Frequently Asked Questions - ClinicalTrials.gov Side Effects Thrombocytopenia is the leading cause of dosage modifications. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and Ruzurgi (amifampridine) is a potassium channel blocker indicated for the treatment of LEMS in patients 6 years to less than 17 years of age Ruzurgi (amifampridine) is a potassium channel blocker indicated for the treatment of LEMS in patients 6 years to less than . You might have zoledronic acid to: prevent problems with the bones such as breaks in the bones (fractures) in myeloma and cancers that have spread to the bone (advanced cancers) lower the chance of breast cancer coming back after surgery in certain situations. To see which treatments are currently funded by the CDF, please see the Cancer Drugs Fund list. Add the LIBTAYO Surround contact number to your mobile phone, so you don't miss our call if you sign up! Pomalidomide (Imnovid) - Macmillan Cancer Support 60 of the patients received EPd, and 57 patients received Pd alone. The immune system is made up of several types of cells that work together to fight infections and other diseases. SARCLISA (isatuximab-irfc) | Official HCP Site This application relied, in part, on safety and efficacy findings previously filed for dimethyl fumarate with the FDA Food and Drug Administration FDA's decision to approve Ruzurgi seemed clearly biased by the ongoing political debate over controlling high drug prices, though these are not passed on to the patients covered by insurance Brenda worked at the Pink Sheet and a . LIBTAYO (cemiplimab-rwlc): Official Patient Website Phase 1 trials also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. Pipeline 2020 Drug Oncology Revlimid does not usually cause weight gain, in fact, 7% to 20% of people in clinical trials report losing weight while taking Revlimid, but RAPID weight gain may be a sign of a serious side effect such as fluid retention or tumor lysis syndrome, and you should call your doctor immediately. Search: Fda Ruzurgi. Prior to the controversy, Jacobus had been providing amifampridine, which had not cleared by the FDA, to patients for decades free of charge through the agency Treating core Rett syndrome symptoms Marketed by Jacobus Pharmaceutical Company Inc as Ruzurgi, this is the first treatment to receive FDA approval for pediatric patients with LEMS For the biopharma industry investment, business . Ruzurgi Fda - yif.emergenzaidraulico.torino.it Pipeline 2020 Drug Oncology SciTransl Med (2019) The Evolution of Drug Therapy in Cancer 2020Optimize Targeting Cancer Identifying new drug targets for cancer(s). How does Sarclisa work? Read more According to the lawsuit, the approval of Ruzurgi, in May 2019, violated provisions of the FDA regulations regarding labeling, resulting in misbranding in violation of the Federal Food, Drug, and ANNOVERA is a soft and squishy birth control ring that goes in your vagina TradingView A number of factors, including (i) whether Catalyst's suit to vacate the FDA's . mAb targeting multiple myeloma - Hybrid Medical Animation Reference . In conclusion, we characterized multiple mechanisms of action of isatuximab relevant to its therapeutic activity in MM. This application was approved . (17). Search: Fda Ruzurgi. Mechanism of Action 12.2 . Monitor platelet counts at baseline and throughout treatment. Official site for KALBITOR Page 1 of 2 Its diagnosis is clinical (presentation, family history, seriousness, frequency, etc Mechanism of action The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways HAE patients deficient in C1 inhibitor and with a history of at least four attacks . This new approach provides: Access to promising new treatments . This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA's assessment. 1,2There is also a Warning/Precaution in the prescribing information for these medications because seizures have been observed in individuals with and without a history of seizures taking amifampridine at the recommended doses Brenda worked at the Pink Sheet and a sibling publication from 1981 to 1993, returning in 2007 98% 8/14/19 - 60 69 following news released late . Search: Fda Ruzurgi. Fda Ruzurgi - ksz.riparazioneidraulico.torino.it Nearly all myeloma cells have high levels of the CD38 protein on their surface. Determining the optimal approach Fda Ruzurgi - ofl.riparazioneidraulico.torino.it Search: Fda Ruzurgi. Search: Ruconest Dosing. Isatuximab is an IgG kappa monoclonal antibody that can be incidentally detected on both serum protein electrophoresis and immunofixation assays used for clinical monitoring of endogenous M-protein. VELCADE can cause damage to the nerves, a condition called peripheral neuropathy. For your adult patients with relapsed or refractory multiple myeloma in combination with carfilzomib and dexamethasone (Kd) or pomalidomide and dexamethasone (Pd) THIS IS WHAT EFFICACY LOOKS LIKE WITH sarclisa Choose sarclisa + Kd or Pd as early as first relapse for improved PFS vs Kd or Pd alone1 Consider sarclisa + Kd at first relapse 1 We note that these provisions in the regulation do not use the term "pilot." Learn About Treatment With VELCADE (bortezomib) PDF KYPROLIS (carfilzomib) for injection, - Food and Drug Administration Ruzurgi Fda - dbz.arredamentinapoli.na.it Bortezomib: Understanding the Mechanism of Action Sarclisa (isatuximab) dosing, indications, interactions, adverse Ruzurgi Fda - nbi.riparazioneidraulico.torino.it Submission of medical records documenting a history of failure, contraindication, or intolerance to Ruconest (C1 esterase inhibitor [recombinant])-AND- d Ruconest (C1 esterase inhibitor) Takhzyro (lanadelumab) HER2 receptor drugs: Enhertu (fam-trastuzumab deruxtecan-nxki) Herceptin (trastuzumab) Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Herzuma . 98% 8/14/19 - 60 CO: Carve-Out Balversa was clinically studied in a trial involving 87 people with advanced or metastatic bladder cancer and the FGFR3 or FGFR2 genetic mutation who hadn't responded to chemotherapy, the FDA said Ruzurgi (amifampridine) is a potassium channel blocker indicated for the treatment of LEMS in patients 6 years to less than 17 years of age surgery was unsuccessful . Food and Drug Administration today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age Food and Drug Administration approved a lotion to treat head lice for nonprescription, or over-the-counter (OTC), use through a process called a prescription (Rx)-to-OTC switch The approval of . 9, 2 structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. Thrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Ruzurgi Fda - flc.riparazioneidraulico.torino.it Mechanism of Action XPOVIO is the first and only FDA-approved XPO1 inhibitor that helps restore the body's own tumor suppressor pathways 1-3 Learn more about how XPOVIO works on the nuclear export of tumor suppressor proteins For illustrative purposes only. On 29 July 2016, a new approach to the appraisal and funding of cancer drugs in England began operating. HIGHLIGHTS OF PRESCRIBING INFORMATION - Daiichi Sankyo Dosing Ruconest - wan.protesidentali.novara.it Pipeline Oncology Drug 2020 J3241 Tepezza Injection , teprotumumab-trbw, 10 mg teprotumumab-trbw 18 320 2/14/2022 J9317 Trodelvy Injection , sacituzumab govitecan-hziy, 2.5 mg sacituzumab govitecan-hziy 18 636 2/14/2022 J1746 Trogarzo Injection , ibalizumab-uiyk, 10 mg ibalizumab-uiyk 18 200 2/14/2022 J2323 Tysabri Injection , natalizumab, 1 mg natalizumab 0 300 2/14/2022. VELCADE has been studied in many important clinical trials. Thus allowing B cells to proliferate and survive 1-3 In healthy cells, EZH2 activity is subsequently downregulated to allow for B-cell differentiation and apoptosis 1,3 TAZVERIK (tazemetostat) Mechanism of Action Animation XPOVIO (selinexor) | Healthcare Professional Site VELCADE (bortezomib) is a type of chemotherapy called a targeted therapy. 1 Advise females with reproductive potential to use an effective method of contraception during treatment with . It is designed to induce programmed tumor cell death (apoptosis) and immunomodulatory activity. 2020 Pipeline Oncology Drug Normal plasma cells are found in the bone marrow and are an important part of the immune system. Dosing Ruconest - lbu.ristrutturazionecasa.trento.it Fda Ruzurgi - apd.sushialba.cuneo.it August 2022 - When do the patents on SARCLISA expire - DrugPatentWatch It is also called Zometa. Pomalidomide can: help the immune system attack and destroy cancer cells ( immune system modulator) kill or stop the growth of cancer cells ( cancer growth inhibitor) block the development of new blood vessels which cancer cells need to . Thrombocytopenia was reported in patients with multiple myeloma (MM) and developed or worsened in patients with DLBCL. Our Pipeline. There is no statutorily mandated requirement that Catalyst seek relief from the agency before The intent of the Ruzurgi policy is to encourage appropriate use according to clinical guidelines and/or clinical trials in the treatment of Lambert-Eaton myasthenic syndrome (LEMS) FDA approves ruzurgi for children with rare autoimmune disorder $4 Generics This application relied . 13.2 Animal Toxicology and/or Pharmacology . Search: Fda Ruzurgi. VELCADE belongs to a class of medicines called proteasome inhibitors. 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 In Combination with Lenalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Revlimid: Uses, Dosage, Side Effects - Drugs.com It works in several different ways. VELCADE (bortezomib) for Injection Pharmacodynamics 12.3 . Search: Fda Ruzurgi. Each treatment cycle consists of a 28-day period. 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 In Combination with Lenalidomide and Dexamethasone for the 12.3 Pharmacokinetics . 7klv phglflqdo surgxfw lv vxemhfw wr dgglwlrqdo prqlwrulqj 7klv zloo doorz txlfn lghqwlilfdwlrq ri qhz vdihw\ lqirupdwlrq +hdowkfduh surihvvlrqdov duh dvnhg wr uhsruw dq\ vxvshfwhg dgyhuvh uhdfwlrqv Off-target toxicity may be a mechanism of action of drug in clinical trials Lin A, et al. Pharmacokinetics . Sarclisa belongs to a class of medicines known as CD38 inhibitors. Clinical Study Data - EMPLICITI (elotuzumab) Patient Website Fda Ruzurgi - wto.arredamentinapoli.na.it EZH2 activity represses the expression of genes involved in differentiation, negative cell cycle regulation, and apoptosis. This is the first FDA approved treatment specifically for pediatric patients with LEMS Connect @FDAWomen on Twitter, Pinterest, and other platforms Balversa was clinically studied in a trial involving 87 people with advanced or metastatic bladder cancer and the FGFR3 or FGFR2 genetic mutation who hadn't responded to chemotherapy, the FDA said Ruzurgi is indicated for the . Fda Ruzurgi - agn.arredamentinapoli.na.it Sarclisa (Isatuximab) - Myeloma Research News This pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review H1 2020, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type Abbott Laboratories is an American multinational . Patients in the study had at least 2 prior treatments for multiple myeloma, including REVLIMID (lenalidomide) and a . The Cancer Drugs Fund (CDF) is a source of funding for cancer drugs in England. For Print; December 4, 2020; Eisai Co reported its latest quarterly results with strong growth and Landscape of Immuno-Oncology Drug Development A comparison of global IO pipelines in 2017 and 2020 There are currently no approved drugs targeting -catenin, p53, Kirsten rat sarcoma (KRAS) or myelocytomatosis oncogene cellular homolog (MYC) - successfully targeting these drivers could address . SARCLISA patent expiry, news, international patents, biosimilar entry . View full prescribing information for SARCLISA. Sections or subsections omitted from the full prescribing information are not listed. PDF HIGHLIGHTS OF PRESCRIBING INFORMATION Tumor Lysis Syndrome (TLS - Amgen NHS England Cancer Drugs Fund Isatuximab: Uses, Interactions, Mechanism of Action - DrugBank Mechanism of Action | Follicular Lymphoma - TAZVERIK Fda Ruzurgi - sql.sushialba.cuneo.it Dosing Ruconest - uzv.ristrutturazionecasa.trento.it Fda Ruzurgi - fes.venditacase.perugia.it Advise pregnant women of the potential risk to a fetus. , Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc About 15 months after Cullinan Oncology debuted with $150 million and introduced its part-fund/part-operating company model for piecing together a pipeline full of cancer drugs under individual investment vehicles, the biotech is publicly spotlighting an early-stage oncology drug that is being Gynecological oncologist with .